OCS vs SANA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
OCS · Oculis$7.06 ▼ 5.11%
SANA · Sana Biotechnology$1.59 ▼ 8.62%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- OCS -63.4%
- SANA -55.1%
Head to head
| Metric | OCS | SANA |
|---|---|---|
| Price | $7.06 | $1.59 |
| Change today | ▼ 5.11% | ▼ 8.62% |
| Market cap | $437.15M | $476.42M |
| Return, 3 months | -46.4% | -57.9% |
| Return, year to date | -64.6% | -60.9% |
| Return, 1 year | -63.3% | -51.7% |
| P/E (TTM) | – | – |
| P/B | 1.8 | 2.6 |
| P/E percentile vs own 5y | 64th | 39th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -8.2% | +148.4% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -47.5% | -79.5% |
| Analyst target vs. price | +461.9% | +403.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 36 | 24 |
| 30-day volatility | 58.7% | 83.1% |
| Max drawdown, 1 year | -79.1% | -69.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SANA is the largest of the group by market value.
- SANA has returned the most over the past year.
- OCS has been the calmest stock over the last 30 days.